Toinv ... we think a lot alike, except you are more organized, articulate, and take the time to do research. Great post.

Regarding the " -OR- " part .... is it ABL?

Personally I don't think the problem is ABL itself - it is more about understanding it better, aligning proper targets, and proving it under the industry standards. Always so close, but no cigar, but great new data for refined directions. Maybe BoM2 is the ticket?

ABL is great, changes bio markers safely. Learn how to properly target, and document the correct benefits, in a study.

Learning process. Refinement. A better more dialed in study (ala BoM2), geared to specific strengths, where you already KNOW the results from past work, and for indications financially worth the squeese.

But surely, the past study "failures" (no matter how close), and continual MGT performance and trust issues, make it a more difficult sale.

Still, as this epi market emerges and approaches, somebody competitive is going to want this book of work, and property, at some point. I'm always confused lol, but still adding on as I can. Someday!